Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00025558 · ClinicalTrials.gov registry record · Phase 1

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer

A Phase 1 study, sponsored by NYU Langone Health.

Completed
Registry status
Phase 1
Development phase

NCT00025558 is a Phase 1 study that has completed, run by NYU Langone Health.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00025558, a Phase 1 study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide, thiotepa, and carboplatin followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have brain cancer.

Interventions

  • DRUG carboplatin
  • DRUG temozolomide
  • BIOLOGICAL filgrastim
  • DRUG thiotepa
  • PROCEDURE autologous bone marrow transplantation

Trial Details

FieldValue
Start Date 2000-10
Phase Phase 1

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT00025558

The ClinicalTrials.gov registry entry for NCT00025558 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.

NCT00025558 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00025558 about?

NCT00025558 is a clinical study titled "Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I tri...

What is the current status of trial NCT00025558?

This trial is currently completed. It is a Phase 1 study. The study started on 2000-10.

What interventions are being tested in trial NCT00025558?

The interventions under investigation include: carboplatin (DRUG), temozolomide (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), autologous bone marrow transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00025558?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.